Download PDF
Hamostaseologie 2020; 40(04): 485-490
DOI: 10.1055/a-1223-3353
Review Article

The Art of Detecting Antibodies against Factor VIII

Andreas Tiede
1   Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
,
Lorenzo Alberio
2   Service et Laboratoire Central d'Hématologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Antibodies against factor VIII (FVIII) can be detected based on their ability to neutralize the procoagulant activity of FVIII (neutralizing antibodies, inhibitors), or based on their specific binding capacity to FVIII protein. This article reviews the available assays and their clinical interpretation in patients with congenital and acquired hemophilia.

Zusammenfassung

Antikörper gegen Faktor VIII (FVIII) können anhand ihrer neutralisierenden Funktion gegenüber der prokoagulatorischen FVIII Aktivität oder anhand ihrer Bindung an das FVIII-Protein nachgewiesen werden. Dieser Artikel gibt einen Überblick über die verfügbaren Laborteste und ihre klinische Interpretation bei Patienten mit angeborener oder erworbener Hämophilie.

Keywords

coagulation - assay - inhibitor - autoantibodies - Bethesda assay

Schlüsselwörter

Gerinnung - Laborteste - Hemmkörper - Autoantikörper - Bethesda-Test

Disclosures

None.




Publication History

Received: 15 May 2020

Accepted: 20 July 2020

Article published online:
22 September 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Marder VJ, Mannucci PM, Firkin BG, Hoyer LW, Meyer D. Standard nomenclature for factor VIII and von Willebrand factor: a recommendation by the International Committee on Thrombosis and Haemostasis. Thromb Haemost 1985; 54 (04) 871-872
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Kasper CK, Aledort L, Aronson D. et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34 (02) 612
    PubMedGoogle Scholar
  • 3 Verbruggen B, van Heerde WL, Laros-van Gorkom BA. Improvements in factor VIII inhibitor detection: from Bethesda to Nijmegen. Semin Thromb Hemost 2009; 35 (08) 752-759
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73 (02) 247-251
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Kershaw GW, Chen LS, Jayakodi D, Dunkley SM. Validation of 4% albumin as a diluent in the Bethesda assay for FVIII inhibitors. Thromb Res 2013; 132 (06) 735-741
    CrossrefPubMedGoogle Scholar
  • 6 Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982; 60 (05) 1103-1109
    CrossrefPubMedGoogle Scholar
  • 7 Batty P, Platton S, Bowles L, Pasi KJ, Hart DP. Pre-analytical heat treatment and a FVIII ELISA improve factor VIII antibody detection in acquired haemophilia A. Br J Haematol 2014; 166 (06) 953-956
    CrossrefPubMedGoogle Scholar
  • 8 Boylan B, Miller CH. Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels. Haemophilia 2018; 24 (03) 487-491
    CrossrefPubMedGoogle Scholar
  • 9 Uchida N, Sambe T, Yoneyama K. et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 2016; 127 (13) 1633-1641
    CrossrefPubMedGoogle Scholar
  • 10 Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost 2019; 119 (07) 1084-1093
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Jenkins PV, Bowyer A, Burgess C. et al. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia 2020; 26 (01) 151-155
    CrossrefPubMedGoogle Scholar
  • 12 Batsuli G, Zimowski KL, Tickle K, Meeks SL, Sidonio Jr RF. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia 2019; 25 (05) 789-796
    CrossrefPubMedGoogle Scholar
  • 13 Nogami K, Soeda T, Matsumoto T, Kawabe Y, Kitazawa T, Shima M. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies. J Thromb Haemost 2018; 16 (07) 1383-1390
    CrossrefPubMedGoogle Scholar
  • 14 Khandelwal A, Phua CW, Chaudhry HR. et al. Confounding effect of therapeutic protamine and heparin levels on routine and special coagulation testing. Blood Coagul Fibrinolysis 2020; 31 (01) 60-64
    CrossrefPubMedGoogle Scholar
  • 15 Tripodi A, Mancuso ME, Chantarangkul V. et al. Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants. Clin Chem 2005; 51 (10) 1883-1885
    CrossrefPubMedGoogle Scholar
  • 16 Miller CH, Rice AS, Boylan B. et al. Hemophilia Inhibitor Research Study Investigators. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost 2013; 11 (07) 1300-1309
    CrossrefPubMedGoogle Scholar
  • 17 de Maistre E, Wahl D, Perret-Guillaume C. et al. A chromogenic assay allows reliable measurement of factor VIII levels in the presence of strong lupus anticoagulants. Thromb Haemost 1998; 79 (01) 237-238
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Payne AB, Miller CH, Ellingsen D, Driggers J, Boylan B, Bean CJ. Reagent substitution in the chromogenic Bethesda assay for factor VIII inhibitors. Haemophilia 2019; 25 (05) e342-e344
    CrossrefPubMedGoogle Scholar
  • 19 Türkantoz H, Königs C, Knöbl P. et al. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: data from the GTH-AH 01/2010 Study. J Thromb Haemost 2020; 18 (01) 36-43
    CrossrefPubMedGoogle Scholar
  • 20 Abou-Ismail MY, Vuyyala S, Prunty J, Schmaier AH, Nayak L. Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors. Haemophilia 2020
    PubMedGoogle Scholar
  • 21 Bonar RA, Favaloro EJ, Marsden K. External quality assessment of factor VIII inhibitor assays. Semin Thromb Hemost 2013; 39 (03) 320-326
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Werwitzke S, Geisen U, Nowak-Göttl U. et al. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study. J Thromb Haemost 2016; 14 (05) 940-947
    CrossrefPubMedGoogle Scholar
  • 23 Whelan SF, Hofbauer CJ, Horling FM. et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013; 121 (06) 1039-1048
    CrossrefPubMedGoogle Scholar
  • 24 Tiede A, Hofbauer CJ, Werwitzke S. et al. Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study. Blood 2016; 127 (19) 2289-2297
    CrossrefPubMedGoogle Scholar
  • 25 Kahle J, Orlowski A, Stichel D. et al. Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A. Blood 2017; 130 (06) 808-816
    CrossrefPubMedGoogle Scholar
  • 26 Hofbauer CJ, Whelan SF, Hirschler M. et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood 2015; 125 (07) 1180-1188
    CrossrefPubMedGoogle Scholar
  • 27 Hofbauer CJ, Kepa S, Schemper M. et al. FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors. Blood 2016; 128 (02) 293-296
    CrossrefPubMedGoogle Scholar
  • 28 Montalvão SA, Tucunduva AC, Siqueira LH, Sambo AL, Medina SS, Ozelo MC. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients. Haemophilia 2015; 21 (05) 686-692
    CrossrefPubMedGoogle Scholar